Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2002 June;137(3) > Giornale Italiano di Dermatologia e Venereologia 2002 June;137(3):181-7

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014


eTOC

 

ORIGINAL ARTICLES  


Giornale Italiano di Dermatologia e Venereologia 2002 June;137(3):181-7

language: English

Itraconazole: new horizons

Caputo R., Barbareschi M.

Insitute of Dermatological Sciences IRCCS Ospedale Maggiore Policlinico University of Milan, Milan


PDF  


Background. The double action—antimycotic and anti-inflammatory—of itraconazole, has opened new horizons in the treatment of a number of inflammatory skin disorders in which Malassezia yeasts seem to play a pathogenetic role.
Methods. An open study was carried out on 185 patients, including: 160 patients affected by seborrhoeic dermatitis; 5 patients with Malassezia folliculitis; 8 patients with peri-oral dermatitis and papulo-pustular rosacea; 6 patients with adult atopic dermatitis of the face and the neck; and 6 patients with palmoplantar amicrobic pustulosis. In all patients the basic treatment schedule was itraconazole 200 mg/day for 7 days.
Results. A marked reduction of signs and symptoms of these diseases was obtained.
Conclusions. Itraconazole is a drug to be considered in the treatment of this group of conditions, particularly for seborrhoeic dermatitis and Malassezia folliculitis

top of page

Publication History

Cite this article as

Corresponding author e-mail